Alcon Sees Another Bullish Rating After Clear Portfolio Growth Direction In EyecareSeeking Alpha · 3 days ago
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2Business Wire · 4 days ago
Algoma Central Corporation Announces $62.5 million Offering of 6.20% Convertible Unsecured Subordinated DebenturesGlobeNewsWire · 4 days ago
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking EyesBusiness Wire · Oct 16, 2026
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking EyesBusiness Wire · Oct 16, 2026
Credo Expands AI Connectivity Portfolio With 1.6T ZeroFlap ALCZacks Investment Research · Oct 13, 2026Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | $0.77 | $0.84 | Beat |
| May 5, 2026 | $0.80 | $0.85 | Beat |
| Feb 24, 2026 | $0.79 | $0.78 | Miss |
| Nov 11, 2025 | $0.77 | $0.79 | Beat |
| Aug 19, 2025 | $0.71 | $0.76 | Beat |
| May 13, 2025 | $0.76 | $0.73 | Miss |